Department of Surgery, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108, USA; School of Medicine, University of Missouri-Kansas City, 2411 Holmes St, Kansas City, MO 64108, USA.
Department of Surgery, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108, USA.
J Pediatr Surg. 2020 Nov;55(11):2352-2355. doi: 10.1016/j.jpedsurg.2019.12.023. Epub 2020 Jan 10.
Primary fibrinolysis for pediatric empyema has become standard of care at our institution. Early study of our protocol revealed a 16% thoracoscopic decortication rate after primary fibrinolysis. We now report the frequency with which children progress to operation with maturation of the protocol.
A database of patients diagnosed with empyema between September 2014 and March 2019 was examined. Patients who underwent tissue plasminogen activator (tPA) therapy with or without subsequent video-assisted thoracoscopic (VATS) decortication were included. Patients with additional indications for tube thoracostomy or VATS were excluded.
Forty-eight patients were included. Median age was 4.5 years [IQR 2-9.3]. Median length of stay (LOS) was 8 days [IQR 6-11]. No patients underwent primary VATS. Median days with a chest tube was 5 [IQR 5-6] and median number of doses of tPA was 3 [IQR 3-3]. Seven patients (14.6%) had a chest tube replaced without undergoing VATS. The VATS rate was 4.2% in the first half of this study but 0% in the last 33 months.
Thoracoscopic decortication is rarely necessary in children with empyema. Raising the threshold for surgical intervention and utilizing further nonoperative measures can avoid an operation in most children without increasing in-hospital length of stay.
IV.
在我院,小儿脓胸的主要纤溶治疗已成为常规治疗。我们最初的研究方案显示,在进行主要纤溶治疗后,有 16%的患儿需要进行胸腔镜去纤维蛋白治疗。本研究旨在报告随着方案的成熟,有多少患儿需要手术治疗。
我们对 2014 年 9 月至 2019 年 3 月期间诊断为脓胸的患者的数据库进行了检查。包括接受组织型纤溶酶原激活剂(tPA)治疗的患者,无论是否随后进行胸腔镜辅助(VATS)去纤维蛋白治疗。不包括因其他适应证需要进行胸腔管引流或 VATS 的患者。
共纳入 48 例患者。中位年龄为 4.5 岁[IQR 2-9.3]。中位住院时间(LOS)为 8 天[IQR 6-11]。没有患者行初次 VATS。中位带管时间为 5 天[IQR 5-6],中位 tPA 剂量为 3 次[IQR 3-3]。7 例(14.6%)患者在未行 VATS 的情况下更换了胸腔引流管。在前半段研究中,VATS 率为 4.2%,但在最后 33 个月中为 0%。
脓胸患儿很少需要进行胸腔镜去纤维蛋白治疗。提高手术干预的阈值并利用进一步的非手术措施,可以避免大多数患儿进行手术,而不会延长住院时间。
IV 级。